Funding Opportunity RFA-DA-21-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA isto develop tools and technologies to conduct cientifically rigorous, ethical, efficient, and cost-effective research infrastructure that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should to answer crucial scientific questions that require genetic perturbation in a non-human primate model organism with the aim of supporting BRAIN goals of understanding the brain in health an disease.

Notice NOT-MH-20-071 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-020 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-133 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-136 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-137 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-134 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-135 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-788 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-20-045 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) solicits the renewal application for the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Hazards to Humans. The IARC Monographs program, which is supported in part by the NCI, critically evaluates the published scientific evidence on carcinogenic hazards to humans. Monograph volumes are considered critical references that inform health policy and cancer research worldwide about carcinogenic hazards to reduce cancer burden globally.

Notice NOT-NR-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-015 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-075 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-024 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-266 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications for the treatment of many diseases, disorders, and conditions. Given the emphasis on innovation, little or no preliminary data are needed to apply under this FOA. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations in human subjects or animal models, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.

Funding Opportunity RFA-NS-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area. The applicant inst

Funding Opportunity RFA-NS-21-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge. Requirements include 1) a minimum of three research projects; 2) research cores that are each essential to accomplish the aims of at least two proposed research projects, plus an Administrative Core; 3) a mission statement and plan for career enhancement of Center trainees and investigators; and 4) a plan for effective outreach, including dissemination of Udall Center research results, to the local patient and advocacy community. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. A considerable degree of synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. The Udall Center Director (PD/PI) must be an established leader in scientific research with visionary leadership skills and proven expertise.

Notice NOT-AI-20-063 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-061 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-085 from the NIH Guide for Grants and Contracts